Company insider dossier

Ionis Pharmaceuticals Inc insider intelligence

IONS filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
66/100

Accumulation bias

93/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
31 Jul 2026

Investment committee read

Accumulation bias

Priced common-share acquisitions carry more weighted evidence than disposals after freshness, role, size, and duplicate controls.

Watch for market confirmation

Evidence in favour

  • 27 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 20 named insiders rather than one filing source.
  • The latest qualifying evidence is fresh, dated 31 Jul 2026.

Decision risks

  • Qualifying disposal events outnumber acquisitions, although disposals receive a lower directional weight.
Conviction66Accumulation bias
Confidence93Deep evidence
Named insiders20participating in the tape
Controlled events59directional common-share events
Acquisition value$16.8Mnormalized amount
Disposal value$30.1Mnormalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

86.5071.6556.8041.9427.09 Acquisition · 31 Jul 2026 · $258.0KAcquisition · 30 Jul 2026 · $800.7KAcquisition · 15 Jul 2026 · Not reportedAcquisition · 15 Jul 2026 · Not reportedAcquisition · 7 Jul 2026 · Not reportedDisposal · 7 Jul 2026 · $1.3MDisposal · 7 Jul 2026 · $863.6KAcquisition · 7 Jul 2026 · $476.3KDisposal · 7 Jul 2026 · $462.7KDisposal · 7 Jul 2026 · $30.5KDisposal · 1 Jul 2026 · $902.6KAcquisition · 1 Jul 2026 · $460.0KDisposal · 1 Jul 2026 · $7.9KDisposal · 26 Jun 2026 · $4.0MAcquisition · 26 Jun 2026 · $2.8MDisposal · 26 Jun 2026 · $2.1MAcquisition · 26 Jun 2026 · $1.6MDisposal · 26 Jun 2026 · $451.7KDisposal · 26 Jun 2026 · $245.5KAcquisition · 26 Jun 2026 · $219.5KAcquisition · 26 Jun 2026 · $57.7KDisposal · 25 Jun 2026 · $1.7MDisposal · 25 Jun 2026 · $839.5KAcquisition · 25 Jun 2026 · $686.9KDisposal · 24 Jun 2026 · $1.1MAcquisition · 24 Jun 2026 · $474.8KDisposal · 15 Jun 2026 · $587.9KAcquisition · 15 Jun 2026 · $195.4KDisposal · 12 Jun 2026 · $3.0MDisposal · 12 Jun 2026 · $1.5MAcquisition · 12 Jun 2026 · $1.3MAcquisition · 12 Jun 2026 · $1.1MAcquisition · 12 Jun 2026 · $484.1KAcquisition · 12 Jun 2026 · $391.2KDisposal · 1 Jun 2026 · $605.4KAcquisition · 1 Jun 2026 · $195.4KDisposal · 14 May 2026 · $253.3KAcquisition · 14 May 2026 · $105.0KDisposal · 13 May 2026 · $102.7KAcquisition · 13 May 2026 · $42.9KDisposal · 4 May 2026 · $4.5MDisposal · 4 May 2026 · $1.3MAcquisition · 4 May 2026 · $1.0MAcquisition · 4 May 2026 · $722.4KAcquisition · 4 May 2026 · $686.1KAcquisition · 4 May 2026 · $480.6KAcquisition · 4 May 2026 · $424.0KAcquisition · 4 May 2026 · $417.4KDisposal · 1 May 2026 · $636.7KAcquisition · 1 May 2026 · $476.3KDisposal · 1 May 2026 · $106.5KDisposal · 28 Apr 2026 · $116.7KDisposal · 16 Apr 2026 · $419.0KDisposal · 16 Apr 2026 · $368.5KDisposal · 16 Apr 2026 · $73.0KAcquisition · 15 Apr 2026 · Not reportedAcquisition · 15 Apr 2026 · Not reportedAcquisition · 15 Apr 2026 · Not reportedDisposal · 15 Apr 2026 · $340.3KDisposal · 15 Apr 2026 · $41.1KDisposal · 2 Apr 2026 · $458.6KDisposal · 1 Apr 2026 · $1.5MAcquisition · 1 Apr 2026 · $456.7KAcquisition · 1 Apr 2026 · $424.0KDisposal · 1 Apr 2026 · $168.3K
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
56.56 USD
One-week move
+9.3%
Four-week move
-2.9%
Fair-value gap
+10.6%
Trend signal
Inactive
Relative strength
-30.9

Directional balance

Controlled event mix

45.8%acquisition
Acquisition events
27
Disposal events
32
Net value
-$13.3M

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

025 May
501 Jun
1008 Jun
315 Jun
1922 Jun
1829 Jun
806 Jul
613 Jul
020 Jul
227 Jul
003 Aug
010 Aug

Named participants

Insider conviction by person

LOSCALZO, JOSEPHDirector768 events
HAYDEN, MICHAEL RDirector752 events
KORDASIEWICZ, HOLLY B.EVP, Chief Development Officer677 events
MONIA, BRETT PDirector, Chief Executive Officer6610 events
BAROLDI, JOSEPHEVP, Chief Business Officer655 events
BERTHELSEN, SPENCER RDirector634 events
SCHNEIDER, EUGENEEVP, Chf Clinical Develop Ofcr612 events
DIAZ, ALLENE M.Director612 events
KLEIN, JOSEPH IIIDirector5810 events
HANTSON, LUDWIGDirector500 events
REIKES, PETER NDirector500 events
HERMAN, JOAN EDirector500 events

Evidence quality

Security and transaction context

Common equity65
Equity compensation15
Options and derivatives32
Other securities0

Role architecture

Who is participating

Director61
Other executive26
CEO and chair15
Other or unspecified10

Transaction evidence

Auditable IONS filing ledger

Showing 31 to 60 of 112.

YANG, MICHAEL J.Director
AcquisitionEquity compensation
2301 sharesRestricted Stock Unit
Not reportedContext evidence
KLEIN, JOSEPH IIIDirector
DisposalCommon equity
11419 sharesCommon Stock
$902.6KDirectional evidence
KLEIN, JOSEPH IIIDirector
AcquisitionCommon equity
11518 sharesCommon Stock
$460.0KDirectional evidence
KLEIN, JOSEPH IIIDirector
DisposalCommon equity
99 sharesCommon Stock
$7.9KDirectional evidence
BAROLDI, JOSEPHEVP, Chief Business Officer
DisposalOptions and derivatives
3866 sharesNon-Qualified Stock Option (right to buy)
Not reportedContext evidence
BAROLDI, JOSEPHEVP, Chief Business Officer
DisposalOptions and derivatives
1769 sharesNon-Qualified Stock Option (right to buy)
Not reportedContext evidence
MONIA, BRETT PDirector, Chief Executive Officer
DisposalOptions and derivatives
50000 sharesNon-Qualified Stock Option (right to buy)
Not reportedContext evidence
SCHNEIDER, EUGENEEVP, Chf Clinical Develop Ofcr
DisposalOptions and derivatives
26000 sharesNon-Qualified Stock Option (right to buy)
Not reportedContext evidence
MONIA, BRETT PDirector, Chief Executive Officer
DisposalCommon equity
50000 sharesCommon Stock
$4.0MDirectional evidence
MONIA, BRETT PDirector, Chief Executive Officer
AcquisitionCommon equity
50000 sharesCommon Stock
$2.8MDirectional evidence
SCHNEIDER, EUGENEEVP, Chf Clinical Develop Ofcr
DisposalCommon equity
26000 sharesCommon Stock
$2.1MDirectional evidence
SCHNEIDER, EUGENEEVP, Chf Clinical Develop Ofcr
AcquisitionCommon equity
26000 sharesCommon Stock
$1.6MDirectional evidence
BAROLDI, JOSEPHEVP, Chief Business Officer
DisposalCommon equity
5635 sharesCommon Stock
$451.7KDirectional evidence
O'NEIL, PATRICK R.EVP CLO & General Counsel
DisposalCommon equity
3069 sharesCommon Stock
$245.5KDirectional evidence
BAROLDI, JOSEPHEVP, Chief Business Officer
AcquisitionCommon equity
3866 sharesCommon Stock
$219.5KDirectional evidence
BAROLDI, JOSEPHEVP, Chief Business Officer
AcquisitionCommon equity
1769 sharesCommon Stock
$57.7KDirectional evidence
MONIA, BRETT PDirector, Chief Executive Officer
DisposalOptions and derivatives
21072 sharesNon-Qualified Stock Option (right to buy)
Not reportedContext evidence
MONIA, BRETT PDirector, Chief Executive Officer
DisposalCommon equity
21072 sharesCommon Stock
$1.7MDirectional evidence
SWAYZE, ERICEVP Research
DisposalCommon equity
10602 sharesCommon Stock
$839.5KDirectional evidence
MONIA, BRETT PDirector, Chief Executive Officer
AcquisitionCommon equity
21072 sharesCommon Stock
$686.9KDirectional evidence
MONIA, BRETT PDirector, Chief Executive Officer
DisposalOptions and derivatives
14565 sharesNon-Qualified Stock Option (right to buy)
Not reportedContext evidence
MONIA, BRETT PDirector, Chief Executive Officer
DisposalCommon equity
14565 sharesCommon Stock
$1.1MDirectional evidence
MONIA, BRETT PDirector, Chief Executive Officer
AcquisitionCommon equity
14565 sharesCommon Stock
$474.8KDirectional evidence
BERTHELSEN, SPENCER RDirector
DisposalOptions and derivatives
8000 sharesNon-Qualified Stock Option (right to buy)
Not reportedContext evidence
BERTHELSEN, SPENCER RDirector
DisposalCommon equity
8000 sharesCommon Stock
$587.9KDirectional evidence
BERTHELSEN, SPENCER RDirector
AcquisitionCommon equity
8000 sharesCommon Stock
$195.4KDirectional evidence
KORDASIEWICZ, HOLLY B.EVP, Chief Development Officer
DisposalOptions and derivatives
7951 sharesNon-Qualified Stock Option (right to buy)
Not reportedContext evidence
KORDASIEWICZ, HOLLY B.EVP, Chief Development Officer
DisposalOptions and derivatives
21000 sharesNon-Qualified Stock Option (right to buy)
Not reportedContext evidence
KORDASIEWICZ, HOLLY B.EVP, Chief Development Officer
DisposalOptions and derivatives
19895 sharesNon-Qualified Stock Option (right to buy)
Not reportedContext evidence
KORDASIEWICZ, HOLLY B.EVP, Chief Development Officer
DisposalOptions and derivatives
12000 sharesNon-Qualified Stock Option (right to buy)
Not reportedContext evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context